Thermo Fisher Scientific (TMO) : Pictet Cie (europe) Sa scooped up 5,865 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 159,402 shares of Thermo Fisher Scientific which is valued at $23,573,962.Thermo Fisher Scientific makes up approximately 4.84% of Pictet Cie (europe) Sa’s portfolio.
Other Hedge Funds, Including , Puplava Financial Services reduced its stake in TMO by selling 1,397 shares or 13.77% in the most recent quarter. The Hedge Fund company now holds 8,748 shares of TMO which is valued at $1,293,742. Thermo Fisher Scientific makes up approx 0.79% of Puplava Financial Services’s portfolio.Td Asset Management Inc reduced its stake in TMO by selling 25,803 shares or 5.01% in the most recent quarter. The Hedge Fund company now holds 489,025 shares of TMO which is valued at $71,872,004. Thermo Fisher Scientific makes up approx 0.14% of Td Asset Management Inc’s portfolio. Braun Stacey Associates Inc added TMO to its portfolio by purchasing 96,307 company shares during the most recent quarter which is valued at $14,154,240. Thermo Fisher Scientific makes up approx 0.92% of Braun Stacey Associates Inc’s portfolio.Whittier Trust Co boosted its stake in TMO in the latest quarter, The investment management firm added 1,665 additional shares and now holds a total of 11,192 shares of Thermo Fisher Scientific which is valued at $1,614,446. Thermo Fisher Scientific makes up approx 0.07% of Whittier Trust Co’s portfolio. Curian Capital sold out all of its stake in TMO during the most recent quarter. The investment firm sold 5,079 shares of TMO which is valued $732,646.
Thermo Fisher Scientific closed down -1.03 points or -0.69% at $147.89 with 15,31,051 shares getting traded on Friday. Post opening the session at $148.37, the shares hit an intraday low of $147.4 and an intraday high of $149.35 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Thermo Fisher Scientific reported $1.80 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.74. The company had revenue of $4294.80 million for the quarter, compared to analysts expectations of $4113.28 million. The company’s revenue was up 9.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.63 EPS.
Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on May 3, 2016 to “Buy”, Firm has raised the Price Target to $ 163 from a previous price target of $160 .Thermo Fisher Scientific was Downgraded by Jefferies to ” Hold” on Apr 29, 2016. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .
Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.